Precigen FY2026 Earnings Forecast Boosted by HC Wainwright

Precigen, Inc. (NASDAQ:PGEN) – Analysts at HC Wainwright raised their FY2026 EPS estimates for shares of Precigen in a research note issued to investors on Thursday, November 5th. HC Wainwright analyst S. Ramakanth now expects that the biotechnology company will earn $0.24 per share for the year, up from their previous forecast of $0.14. HC Wainwright has a “Buy” rating and a $18.00 price target on the stock. The consensus estimate for Precigen’s current full-year earnings is $0.27 per share. HC Wainwright also issued estimates for Precigen’s FY2027 earnings at $0.65 EPS.

Precigen (NASDAQ:PGEN) last issued its earnings results on Wednesday, November 4th. The biotechnology company reported $0.08 earnings per share for the quarter, beating analysts’ consensus estimates of $0.06 by $0.02. The firm had revenue of $74.15 million for the quarter, compared to analyst estimates of $71.55 million. Precigen had a net margin of 15.55% and a return on equity of 86.42%. The company’s quarterly revenue was up 2437.6% on a year-over-year basis. During the same quarter last year, the business posted ($1.06) earnings per share.

Several other equities research analysts also recently weighed in on the company. B. Riley Financial initiated coverage on Precigen in a report on Friday, September 25th. They set a “buy” rating and a $12.00 price objective on the stock. Wall Street Zen raised Precigen from a “buy” rating to a “strong-buy” rating in a report on Sunday. Citigroup reaffirmed a “market outperform” rating on shares of Precigen in a report on Thursday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Precigen in a research report on Thursday, October 15th. Finally, Citizens Jmp lifted their price target on Precigen from $11.00 to $12.00 and gave the company a “market outperform” rating in a research note on Thursday, November 5th. Four analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $13.50.

Precigen Stock Up 5.8%

Shares of NASDAQ:PGEN opened at $4.73 on Monday. The company has a fifty day moving average of $6.93 and a 200-day moving average of $5.29. The company has a market capitalization of $1.69 billion, a PE ratio of 47.30 and a beta of 1.01. The company has a debt-to-equity ratio of 2.15, a quick ratio of 3.89 and a current ratio of 4.58. Precigen has a 52-week low of $3.04 and a 52-week high of $8.98.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. Patient Capital Management LLC bought a new stake in shares of Precigen in the 2nd quarter valued at about $108,511,000. BlackRock Inc. bought a new position in shares of Precigen during the second quarter worth about $97,737,000. Bank of America Corp DE bought a new position in shares of Precigen during the second quarter worth about $10,536,000. Wellington Management Group LLP lifted its stake in shares of Precigen by 9.2% in the second quarter. Wellington Management Group LLP now owns 555,230 shares of the biotechnology company’s stock worth $3,165,000 after acquiring an additional 46,796 shares during the period. Finally, Bank of New York Mellon Corp acquired a new position in shares of Precigen in the second quarter worth approximately $2,705,000. 33.51% of the stock is owned by institutional investors.

Insider Activity at Precigen

In other news, COO Rutul Shah sold 34,658 shares of the firm’s stock in a transaction on Friday, August 21st. The shares were sold at an average price of $7.50, for a total transaction of $259,935.00. Following the completion of the transaction, the chief operating officer owned 465,012 shares of the company’s stock, valued at approximately $3,487,590. This trade represents a 6.94% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Jeffrey Kindler sold 185,000 shares of Precigen stock in a transaction on Wednesday, August 26th. The stock was sold at an average price of $7.44, for a total transaction of $1,376,400.00. Following the transaction, the director owned 17,100 shares in the company, valued at approximately $127,224. This trade represents a 91.54% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 235,000 shares of company stock valued at $1,751,400. Corporate insiders own 41.40% of the company’s stock.

Precigen Company Profile